knowledge -WSS

knowledge

author：hotspot 2025-10-06 06:37:57 - browse：35

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： New weight loss drugs work. But how can they best be used?

WSS

Study says nonprofit hospitals fall short in charity care spending

3 medical device trends to watch in 2024

Federal weight loss drug coverage is 30 years out of date

GSK Flovent asthma inhalers replaced by authorized generics

Chronically ill young patients struggle to find fertility info

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Affirmative action in medical school literally saved lives

Readout LOUD podcast: mifepristone case, GLP

Moonlake's readout produced a cash windfall. Risks remain

Why psychiatrists like me stop taking insurance

Activists slam private health insurers over coverage restrictions

Covid vaccine financial winners and losers, from Pfizer to Novavax

Sports medicine is finally prioritizing gender equality

Federal weight loss drug coverage is 30 years out of date

The cancer drug shortage isn’t new — and neither are the solutions

Goldman Sachs launches $650M fund for life science investments

leisure time

New weight loss drugs work. But how can they best be used?

Supreme Court mifepristone arguments center on docs' right to sue

Scientists boost immune system in aging mice by making it youthful

Patient advocates debate FDA's accelerated approval process

3 trends to watch in health tech's hiring outlook for 2024

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

focus

focus

focus